What is an umbrella review?

An umbrella review synthesizes multiple meta-analyses on a single topic rather than individual studies. It sits at the top of the evidence hierarchy, giving the broadest view of accumulated research. This 2026 review covered 13 separate meta-analyses on inositol and PCOS, then assessed each finding using the GRADE system for evidence quality.

What is the difference between myo-inositol and D-chiro-inositol?

Both are naturally occurring forms of inositol involved in insulin signaling. Myo-inositol is the predominant form in most tissues and showed superior outcomes in this review. D-chiro-inositol at high doses may negatively affect follicle development, which is why the review recommends using it with caution.

How does inositol compare to metformin for PCOS?

This review found inositol performed similarly to metformin across most metabolic and hormonal parameters, with better results on triglycerides and pregnancy outcomes. Inositol also has a more favorable side effect profile. However, both comparisons are based on evidence rated low to moderate quality.

Inositol for PCOS, What 13 Meta-Analyses Found in 2026

PCOS (polycystic ovary syndrome) affects approximately 13% of women of reproductive age globally, making it one of the most common endocrine disorders. Irregular ovulation, elevated androgens, and insulin resistance are its defining features. Inositol supplementation has been studied in this context for years, but a 2026 umbrella review (a synthesis of multiple meta-analyses) published in Frontiers in Endocrinology is the most comprehensive picture of that evidence to date.

Thirteen meta-analyses were included. The findings show consistent signals across hormonal, metabolic, and reproductive outcomes, alongside a clear-eyed assessment of how much confidence those findings warrant.

The evidence quality picture first

Before the numbers: GRADE analysis of the 13 included meta-analyses produced the following distribution.

High quality: 0%
Moderate quality: 18.9%
Low quality: 40%
Very low quality: 41.1%

More than 80% of the evidence base falls in the low or very low category. A consistent direction of effect and a statistically significant result are not the same as high certainty. That distinction matters when translating research into individual decisions.

Hormonal outcomes

Inositol supplementation produced measurable changes across the hormonal markers most relevant to PCOS.

LH reduced by 3.43 IU/L (p<0.00001). Elevated LH is a core driver of anovulation in PCOS. A reduction of this size represents a meaningful hormonal shift.
Free testosterone reduced by 0.02 nmol/L. Androgen excess drives many of PCOS’s visible symptoms, including acne, excess hair growth, and irregular cycles.
SHBG increased by 36.72 nmol/L. Sex hormone-binding globulin binds free androgens, reducing their biological availability. Higher SHBG effectively lowers androgenic activity even when total androgen production is unchanged.

Metabolic outcomes

Insulin resistance is not a side issue in PCOS. In many cases it is the upstream driver, pushing the ovaries toward androgen overproduction. Correcting insulin signaling can shift the entire hormonal picture downstream.

HOMA-IR decreased by 1.14. HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is a standard clinical marker. A decrease of 1.14 points is a clinically relevant improvement in insulin sensitivity.
Fasting insulin decreased by 23.40 pmol/L. The direct measure of fasting insulin confirms the insulin-sensitizing effect.

Reproductive outcomes, the numbers that matter most

Live birth rate RR 2.29 (p=0.03). Women taking inositol were 2.29 times more likely to have a live birth compared to controls.
Ovulation rate RR 2.75 (p<0.0001). The rate of successful ovulation was 2.75 times higher in the inositol group.

These two findings carry the most clinical weight for women with PCOS who are trying to conceive.

Myo-inositol vs D-chiro-inositol

The review’s clearest practical guidance concerns which form of inositol to use. Myo-inositol demonstrated superior outcomes across the board. D-chiro-inositol received a “use with caution” recommendation, based on evidence that excess D-chiro-inositol supplementation may impair follicle maturation, potentially working against reproductive goals.

Most commercial inositol products for PCOS now use myo-inositol or a combination formula with a 40:1 myo-to-D-chiro ratio, which approximates the physiological ratio in healthy ovarian follicles.

How inositol compares to metformin

Metformin is a first-line pharmaceutical used in PCOS management. The review found inositol performed similarly to metformin on most hormonal and metabolic parameters, with an edge on triglyceride reduction and pregnancy outcomes. Inositol also carries a cleaner side effect profile, which is relevant for women who are actively trying to conceive.

The comparison is meaningful but limited by the same evidence quality constraints that apply throughout this review.

Sources

Frontiers in Endocrinology (2026). Umbrella review of inositol supplementation in PCOS. 13 meta-analyses with GRADE evidence assessment.

Source: Frontiers in Endocrinology